ClinicalTrials.gg
CompletedNCT02974868Updated May 26, 2020Results posted

Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata

A Phase 2 interventional study of PF-06651600 and PF-06700841 in Alopecia Areata, sponsored by Pfizer. Completed at 55 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-05-26.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Alopecia Areata by Pfizer — 4 open to participants now, 8 under way, 4 of them phase 3. Alopecia Areata · Pfizer.

Enrollment
6th of 10
142 · median 175
Started
2016
the only one that year
Phase 2
3 of 17
none open now
Registered
1st of 17
by date

Among the 17 studies in Alopecia Areata by Pfizer, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2016, is one of 3 in phase 2, and was the 1st registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

4 of the 17 studies in Alopecia Areata by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Alopecia Areata by Pfizer, or all of them as a file.
02

Study summary

This is a Phase 2a, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 113 weeks. This includes an up to 5 weeks Screening Period, a 24 week Treatment Period, a 4 week Drug Holiday (#1), an up to 12 month Single Blind (investigator open, sponsor open and subject blind) Extension Period, a 4 week drug holiday (#2), a 6 month Cross Over Open Label Extension Period and a 4 week Follow up Period.

03

Conditions studied

  • Alopecia Areata

Keywords

  • Phase 2
  • randomized
  • double-blind
  • placebo
  • alopecia areata
  • safety
  • efficacy
  • JAK
  • janus kinase
  • moderate
  • severe
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects between 18 75 years of age, inclusive, at time of .
  • Must have moderate to severe alopecia areata:

Exclusion criteria

Exclusion Criteria:

  • History of (HIV) or positive HIV serology at screening,
  • Infected with or viruses.
  • Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)
  • Have received any of the following treatment regiments specified in the timeframes outlined below:

Within 6 months of first dose of study drug: Any cell depleting agents Within 12 weeks of first dose of study drug: Any studies with JAK inhibitors; Other biologics Within 8 weeks of first dose of study drug: Participation in other studies involving drug(s) Within 6 weeks of first dose of study drug: Have been vaccinated with live or attenuated .

Within 4 weeks of first dose of study drug: Use of oral immune suppressants; Phototherapy (NB UVB) or broad band phototherapy; Regular use (more than 2 visits per week) of a tanning booth/parlor.

Within 2 week of first dose of study drug: Topical treatments that could affect AA; Herbal medications with unknown properties or known beneficial effects for AA.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    Cohort 1

    PF-06651600

    Drug: PF-06651600

  • Experimental
    Cohort 2

    PF-06700841

    Drug: PF-06700841

  • Placebo comparator
    Cohort placebo

    placebo

    Drug: Placebo

Interventions

  • 200 mg QD during induction and 50 mg QD during Maintenance

  • 60 mg QD during induction and 30 mg QD during maintenance

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24

    SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. Score range: 0-100%. Higher score indicates more severe disease. Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline signifies an improvement. Baseline is defined as the last measurement prior to first dosing (Day 1).

    Time frame: Baseline, Week24

  2. Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Single-Blind Extension (SBE) Period

    An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators. Arms end with "withdrawal Segment" and "retreatment segment" described the same population while in different treatment segment .The reason why count on PF-06700841 differ by 1 participant is that 1 responder directly entered the retreatment segment and skipped the withdrawal segment.

    Time frame: Week 28 up to Week 52

  3. Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Cross-Over Extension (COE) Period

    An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators.

    Time frame: COE day 1 up to end of study

  4. Number of Participants With Laboratory Abnormalities During SBE Period

    Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect \& Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively.

    Time frame: Week 28 up to Week 52 for non-responders and responders in the withdrawal segment, AT day 1 up to AT Week 24 for retreatment segment (AT=active treatment)

  5. Numbers of Participants With Specific Clinical Laboratory Abnormalities During COE Period

    Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect \& Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively.

    Time frame: COE day 1 up to end of study

Secondary outcomes

  1. Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 -AT/AU Participants

    SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Alopecia totalis (AT): derived as SALT score = 100% at baseline only. Alopecia universalis (AU): derived as SALT score = 100% and both eyelash and eyebrow assessments were "none" at baseline.

    Time frame: Baseline, Week 24

  2. Percentage of Participants Achieving SALT 30 at Week 24

    SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The 90% CI was calculated using Chan and Zhang method.

    Time frame: Baseline, Week 24

  3. Change From Baseline in Severity of Alopecia Tool (SALT) Across Time (Treatment Period)

    SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Least Square Mean and 90% Confidence Interval of Arms (PF-06651600 and PF-06700841) are the Least Square Mean and 90% Confidence Interval for difference from placebo respectively.

    Time frame: Baseline, Weeks 2,4,6,8,12,16,20,24

  4. Percent Change From Baseline in Severity of Alopecia Tool (SALT) Across Time (Treatment Period)

    SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Percent change from baseline is defined as SALT baseline value minus SALT value at a specific visit divided by baseline and multiplying by 100. Positive change from baseline implies an improvement. Least Square Mean and 90% Confidence Interval of Arms (PF-06651600 and PF-06700841) are the Least Square Mean and 90% Confidence Interval for difference from placebo respectively.

    Time frame: Baseline, Weeks 2,4,6,8,12,16,20,24

  5. Percentage of Participants Achieving SALT 30 Across Time (Treatment Period)

    SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.

    Time frame: Baseline, Weeks 2,4,6,8,12,16,20,24

  6. Percentage of Participants Achieving SALT 50 Across Time (Treatment Period)

    SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 50 response is a 50% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.

    Time frame: Baseline, Weeks 2,4,6,8,12,16,20,24

  7. Percentage of Participants Achieving SALT 75 Across Time (Treatment Period)

    SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 75 response is a 75% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.

    Time frame: Baseline, Weeks 2,4,6,8,12,16,20,24

  8. Percentage of Participants Achieving SALT 90 Across Time (Treatment Period)

    SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 90 response is a 90% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.

    Time frame: Baseline, Weeks 2,4,6,8,12,16,20,24

  9. Percentage of Participants Achieving SALT 100 Across Time (Treatment Period)

    SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 100 response is a 100% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.

    Time frame: Baseline, Weeks 2,4,6,8,12,16,20,24

  10. Number of Participants With the IGA Score Change (Treatment Period)

    The clinical evaluator of alopecia areata (AA) will perform an assessment of the overall improvement of AA and assign an Investigator Global Assessment (IGA) score(ranging from 0 to 5) with higher score representing higher regrowth rate. Baseline is defined as the last measurement prior to first dosing (Day 1).

    Time frame: baseline, Week 2,4,6,8,12,16,20,24

  11. Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Treatment Period

    An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators.

    Time frame: baseline up to Week 24

  12. Number of Participants With Laboratory Abnormalities During Treatment Period

    Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect \& Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively.

    Time frame: Baseline up to Week 24

  13. Time to Achieve the Retreatment Criteria During the Withdrawal/Retreatment Part of the Extension Period Among Subjects Who Achieved Primary Endpoint at Week 24 (SBE Period)

    Time to re-treatment (weeks) = (date of re-treatment criteria met - date at Week 24 +1)/7. The calendar time to retreatment was calculated. Baseline is defined as Week 24 measurement. The duration in Drug Holiday #1 (ranging from 2-6 weeks) is counted in the Kaplan-Meier analysis. One subject directly entered the re-treatment period and hence is censored at baseline in the Kaplan-Meier analysis.

    Time frame: Week 24 up to Week 52

  14. Change From Baseline in SALT Across Time (SBE Period)

    SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Least Square Mean and 90% confidence interval in this outcome measurement is the LSM and 90%CI for difference from initial 24-week treatment period placebo respectively.

    Time frame: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)

  15. Percentage of Participants Achieving SALT 30 Across Time (SBE Period)

    SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.

    Time frame: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)

  16. Percentage of Participants Achieving SALT 50 Across Time (SBE Period)

    SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 50 response is a 50% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.

    Time frame: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)

  17. Percentage of Participants Achieving SALT 75 Across Time (SBE Period)

    SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 75 response is a 75% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.

    Time frame: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)

  18. Percentage of Participants Achieving SALT 90 Across Time (SBE Period)

    SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 90 response is a 90% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.

    Time frame: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)

  19. Percentage of Participants Achieving SALT 100 Across Time (SBE Period)

    SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 100 response is a 100% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.

    Time frame: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)

07

Results

Posted May 26, 2020

Participant flow

The study had a 24 week Treatment Period, a 4 week Drug Holiday, an up to 48 weeks(24 weeks + additional 24 Weeks for those received active retreatment) Single Blind Extension Period, a 4 week Drug Holiday, a 24 weeks Cross Over Open Label Extension Period.

Initial 24-Week Treatment Period (TP)
Participant flow — Initial 24-Week Treatment Period (TP)
MilestonePlacebo for PF-06651600Placebo for PF-06700841PF-06651600PF-06700841
Started24234847
Completed20144535
Not completed49312
Withdrew: Adverse event1124
Withdrew: Others3818
Single-Blind Extension (SBE) Period
Participant flow — Single-Blind Extension (SBE) Period
MilestonePlacebo for PF-06651600Placebo for PF-06700841PF-06651600PF-06700841
Started17123829
Completed15112723
Not completed21116
Withdrew: Ae & withdraw by participants21116
Cross-Over Extension (COE) Period
Participant flow — Cross-Over Extension (COE) Period
MilestonePlacebo for PF-06651600Placebo for PF-06700841PF-06651600PF-06700841
Started72113
Completed5183
Not completed2130
Withdrew: Withdrawal by subject2130

Outcome measures

PrimaryChange From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. Score range: 0-100%. Higher score indicates more severe disease. Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline signifies an improvement. Baseline is defined as the last measurement prior to first dosing (Day 1).

Time frame:
Baseline, Week24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24
units on a scalePF-06651600PF-06700841Placebo
Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 2432.54 (25.35 to 39.74)50.59 (43.15 to 58.02)1.41 (-6.03 to 8.85)
Statistical analysis
  • PF-06651600 vs Placebo · Mixed Model Repeated Measure (MMRM) · p = <.0001 (Hochberg P-value (one-sided)) · Mean of difference from placebo: 31.14 · 95% CI 18.78 to 43.50MMRM contains fixed factors of treatment, week, baseline, treatment by week and treatment by baseline interaction and a random effect for subject.
  • PF-06700841 vs Placebo · Mixed Model Repeated Measure (MMRM) · p = <.0001 (Hochberg P-value (one-sided)) · Mean of difference from placebo: 49.18 · 95% CI 36.62 to 61.74MMRM contains fixed factors of treatment, week, baseline, treatment by week and treatment by baseline interaction and a random effect for subject.
SecondaryChange From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 -AT/AU Participants

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Alopecia totalis (AT): derived as SALT score = 100% at baseline only. Alopecia universalis (AU): derived as SALT score = 100% and both eyelash and eyebrow assessments were "none" at baseline.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 -AT/AU Participants
units on a scalePF-06651600-AT/AUPF-06700841-AT/AUPlacebo-AT/AU
Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 -AT/AU Participants27.59 (15.24 to 39.94)48.42 (36.38 to 60.47)1.81 (-11.00 to 14.63)
Statistical analysis
  • PF-06651600-AT/AU vs Placebo-AT/AU · Mixed Model Repeated Measure (MMRM) · p = 0.0094 · Mean of difference from placebo: 25.78 · 90% CI 7.98 to 43.58MMRM contains fixed factors of treatment, week, baseline, treatment by week and treatment by baseline interaction and a random effect for subject.
  • PF-06700841-AT/AU vs Placebo-AT/AU · Mixed Model Repeated Measure · p = <.0001 · Mean of difference from placebo: 46.61 · 90% CI 29.02 to 64.20MMRM contains fixed factors of treatment, week, baseline, treatment by week and treatment by baseline interaction and a random effect for subject.
PrimaryNumber of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Single-Blind Extension (SBE) Period

An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators. Arms end with "withdrawal Segment" and "retreatment segment" described the same population while in different treatment segment .The reason why count on PF-06700841 differ by 1 participant is that 1 responder directly entered the retreatment segment and skipped the withdrawal segment.

Time frame:
Week 28 up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Single-Blind Extension (SBE) Period
ParticipantsActive Non-responders on PF-06651600Placebo Non-responders on PF-06651600Active Non-responders on PF-06700841Placebo Non-responders on PF-06700841Non-Retreated PF-06651600 Responders in the Withdrawal SegmentRetreated PF-06651600 Responders in the Withdrawal SegmentNon-Retreated PF-06700841 Responders in the Withdrawal SegmentRetreated PF-06700841 Responders in the Withdrawal SegmentRetreated PF-06651600 Responders in the Retreatment SegmentRetreated Responders on PF-06700841 in the Retreatment Segment
TEAE (All Causalities)8124104369119
TEAE (Treatment Related)5101010322
PrimaryNumber of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Cross-Over Extension (COE) Period

An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators.

Time frame:
COE day 1 up to end of study
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Cross-Over Extension (COE) Period
ParticipantsCOE-PF-06651600COE-PF-06700841
TEAE (All Causalities)49
TEAE (Treatment Related)23
PrimaryNumber of Participants With Laboratory Abnormalities During SBE Period

Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect \& Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively.

Time frame:
Week 28 up to Week 52 for non-responders and responders in the withdrawal segment, AT day 1 up to AT Week 24 for retreatment segment (AT=active treatment)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities During SBE Period
ParticipantsActive Non-responders on PF-06651600Placebo Non-responders on PF-06651600Active Non-responders on PF-06700841Placebo Non-responders on PF-06700841Non-Retreated PF-06651600 Responders in the Withdrawal SegmentRetreated PF-06651600 Responders in the Withdrawal SegmentNon-Retreated PF-06700841 Responders in the Withdrawal SegmentRetreated PF-06700841 Responders in the Withdrawal SegmentRetreated PF-06651600 Responders in the Retreatment SegmentRetreated Responders on PF-06700841 in the Retreatment Segment
With abnormalities without regard to baseline1311411697101114
Meeting Retest Criteria3527203244
Meeting Discontinuation Criteria0000000010
PrimaryNumbers of Participants With Specific Clinical Laboratory Abnormalities During COE Period

Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect \& Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively.

Time frame:
COE day 1 up to end of study
Reported as:
Count of participants · Participants
Numbers of Participants With Specific Clinical Laboratory Abnormalities During COE Period
ParticipantsCOE-PF-06651600COE-PF-06700841
With abnormalities without regard to baseline511
Meeting Retest Criteria16
Meeting Discontinuation Criteria00
SecondaryPercentage of Participants Achieving SALT 30 at Week 24

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The 90% CI was calculated using Chan and Zhang method.

Time frame:
Baseline, Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving SALT 30 at Week 24
percentage of participantsPF-06651600PF-06700841Placebo
Percentage of Participants Achieving SALT 30 at Week 2450.0 (37.6 to 62.4)63.8 (51.3 to 74.9)2.1 (0.2 to 8.8)
Statistical analysis
  • PF-06651600 vs Placebo · Chan and Zhang method · p = <.0001 · Difference in percentage from placebo: 47.9 · 90% CI 34.2 to 60.7
  • PF-06700841 vs Placebo · Chan and Zhang method · p = <.0001 · Difference in percentage from placebo: 61.7 · 90% CI 48.2 to 73.6
SecondaryChange From Baseline in Severity of Alopecia Tool (SALT) Across Time (Treatment Period)

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Least Square Mean and 90% Confidence Interval of Arms (PF-06651600 and PF-06700841) are the Least Square Mean and 90% Confidence Interval for difference from placebo respectively.

Time frame:
Baseline, Weeks 2,4,6,8,12,16,20,24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Severity of Alopecia Tool (SALT) Across Time (Treatment Period)
units on a scalePF-06651600PF-06700841Placebo
Week 2-0.74 (-2.06 to 0.59)-0.93 (-2.27 to 0.40)1.18 (0.23 to 2.13)
Week 42.93 (-1.32 to 7.17)7.70 (3.43 to 11.97)0.85 (-2.20 to 3.90)
Week 612.44 (5.42 to 19.45)19.37 (12.29 to 26.45)1.32 (-3.72 to 6.35)
Week 818.49 (9.57 to 27.41)29.30 (20.28 to 38.32)1.77 (-4.63 to 8.17)
Week 1224.49 (14.90 to 34.09)36.57 (26.86 to 46.29)1.62 (-5.26 to 8.50)
Week 1627.59 (17.67 to 37.50)41.16 (31.11 to 51.22)1.61 (-5.49 to 8.72)
Week 2029.32 (19.06 to 39.57)45.55 (35.14 to 55.97)1.62 (-5.73 to 8.98)
Week 2431.14 (20.79 to 41.49)49.18 (38.66 to 59.70)1.41 (-6.03 to 8.85)
SecondaryPercent Change From Baseline in Severity of Alopecia Tool (SALT) Across Time (Treatment Period)

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Percent change from baseline is defined as SALT baseline value minus SALT value at a specific visit divided by baseline and multiplying by 100. Positive change from baseline implies an improvement. Least Square Mean and 90% Confidence Interval of Arms (PF-06651600 and PF-06700841) are the Least Square Mean and 90% Confidence Interval for difference from placebo respectively.

Time frame:
Baseline, Weeks 2,4,6,8,12,16,20,24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Severity of Alopecia Tool (SALT) Across Time (Treatment Period)
percent changePF-06651600PF-06700841Placebo
Week 2-0.76 (-2.26 to 0.75)-1.13 (-2.64 to 0.39)1.26 (0.18 to 2.33)
Week 43.99 (-0.86 to 8.83)9.70 (4.83 to 14.57)0.53 (-2.96 to 4.01)
Week 615.88 (7.84 to 23.91)22.88 (14.77 to 30.99)1.02 (-4.75 to 6.80)
Week 823.22 (13.15 to 33.29)34.78 (24.59 to 44.96)1.31 (-5.91 to 8.54)
Week 1230.99 (19.93 to 42.05)44.17 (32.97 to 55.37)0.99 (-6.94 to 8.92)
Week 1635.14 (23.65 to 46.62)49.99 (38.35 to 61.64)0.86 (-7.38 to 9.09)
Week 2037.31 (25.37 to 49.25)55.46 (43.34 to 67.58)0.91 (-7.65 to 9.47)
Week 2439.67 (27.66 to 51.68)59.71 (47.51 to 71.92)0.43 (-8.20 to 9.06)
SecondaryPercentage of Participants Achieving SALT 30 Across Time (Treatment Period)

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.

Time frame:
Baseline, Weeks 2,4,6,8,12,16,20,24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving SALT 30 Across Time (Treatment Period)
percentage of participantsPF-06651600PF-06700841Placebo
Week 2-2.1 (-9.7 to 3.7)-2.1 (-9.7 to 3.5)2.1 (0.2 to 8.8)
Week 46.2 (-2.3 to 15.8)12.8 (3.0 to 24.0)2.1 (0.2 to 8.8)
Week 618.7 (7.0 to 31.0)27.7 (15.4 to 40.4)2.1 (0.2 to 8.8)
Week 825.0 (13.2 to 37.4)38.3 (25.8 to 51.4)2.1 (0.2 to 8.8)
Week 1239.5 (26.4 to 52.6)48.9 (35.8 to 61.8)2.1 (0.2 to 8.8)
Week 1645.8 (32.2 to 58.7)55.3 (42.0 to 67.8)2.1 (0.2 to 8.8)
Week 2047.9 (34.2 to 60.7)59.6 (46.3 to 71.7)2.1 (0.2 to 8.8)
Week 2447.9 (34.2 to 60.7)61.7 (48.2 to 73.6)2.1 (0.2 to 8.8)
SecondaryPercentage of Participants Achieving SALT 50 Across Time (Treatment Period)

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 50 response is a 50% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.

Time frame:
Baseline, Weeks 2,4,6,8,12,16,20,24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving SALT 50 Across Time (Treatment Period)
percentage of participantsPF-06651600PF-06700841Placebo
Week 20.0 (-6.2 to 6.1)0.0 (-6.2 to 6.2)0 (0.0 to 5.7)
Week 40.0 (-6.2 to 6.1)10.6 (3.6 to 21.1)0 (0.0 to 5.7)
Week 610.4 (1.1 to 21.1)17.0 (6.5 to 28.8)2.1 (0.2 to 8.8)
Week 818.7 (7.0 to 31.0)29.8 (17.2 to 42.7)2.1 (0.2 to 8.8)
Week 1227.0 (15.0 to 39.6)36.2 (23.8 to 49.2)2.1 (0.2 to 8.8)
Week 1633.3 (20.3 to 46.2)40.4 (27.8 to 53.5)2.1 (0.2 to 8.8)
Week 2033.3 (20.3 to 46.2)46.8 (33.8 to 59.8)2.1 (0.2 to 8.8)
Week 2437.5 (24.5 to 50.6)51.1 (37.9 to 63.8)2.1 (0.2 to 8.8)
SecondaryPercentage of Participants Achieving SALT 75 Across Time (Treatment Period)

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 75 response is a 75% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.

Time frame:
Baseline, Weeks 2,4,6,8,12,16,20,24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving SALT 75 Across Time (Treatment Period)
percentage of participantsPF-06651600PF-06700841Placebo
Week 20.0 (-6.2 to 6.1)0.0 (-6.2 to 6.2)0 (0.0 to 5.7)
Week 40.0 (-6.2 to 6.1)0.0 (-6.2 to 6.2)0 (0.0 to 5.7)
Week 68.3 (1.8 to 18.1)10.6 (3.6 to 21.1)0 (0.0 to 5.7)
Week 812.5 (2.8 to 23.6)23.4 (11.8 to 36.2)2.1 (0.2 to 8.8)
Week 1216.6 (6.3 to 28.6)27.7 (15.4 to 40.4)2.1 (0.2 to 8.8)
Week 1620.8 (8.6 to 33.0)31.9 (19.0 to 44.9)2.1 (0.2 to 8.8)
Week 2025.0 (13.2 to 37.4)38.3 (25.8 to 51.4)2.1 (0.2 to 8.8)
Week 2427.0 (15.0 to 39.6)40.4 (27.8 to 53.5)2.1 (0.2 to 8.8)
SecondaryPercentage of Participants Achieving SALT 90 Across Time (Treatment Period)

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 90 response is a 90% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.

Time frame:
Baseline, Weeks 2,4,6,8,12,16,20,24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving SALT 90 Across Time (Treatment Period)
percentage of participantsPF-06651600PF-06700841Placebo
Week 20.0 (-6.2 to 6.1)0.0 (-6.2 to 6.2)0 (0.0 to 5.7)
Week 40.0 (-6.2 to 6.1)0.0 (-6.2 to 6.2)0 (0.0 to 5.7)
Week 60.0 (-6.2 to 6.1)6.4 (0.2 to 15.7)0 (0.0 to 5.7)
Week 84.2 (-2.0 to 12.5)12.8 (5.2 to 23.6)0 (0.0 to 5.7)
Week 1210.4 (3.4 to 20.7)25.5 (15.4 to 38.1)0 (0.0 to 5.7)
Week 1616.7 (8.6 to 27.7)27.7 (17.2 to 40.3)0 (0.0 to 5.7)
Week 2018.7 (7.0 to 31.0)29.8 (17.2 to 42.7)2.1 (0.2 to 8.8)
Week 2425.0 (15.1 to 37.3)34.0 (22.7 to 47.0)0 (0.0 to 5.7)
SecondaryPercentage of Participants Achieving SALT 100 Across Time (Treatment Period)

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 100 response is a 100% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.

Time frame:
Baseline, Weeks 2,4,6,8,12,16,20,24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving SALT 100 Across Time (Treatment Period)
percentage of participantsPF-06651600PF-06700841Placebo
Week 20.0 (-6.2 to 6.1)0.0 (-6.2 to 6.2)0 (0.0 to 5.7)
Week 40.0 (-6.2 to 6.1)0.0 (-6.2 to 6.2)0 (0.0 to 5.7)
Week 60.0 (-6.2 to 6.1)0.0 (-6.2 to 6.2)0 (0.0 to 5.7)
Week 80.0 (-6.2 to 6.1)2.1 (-3.5 to 9.7)0 (0.0 to 5.7)
Week 122.1 (-3.8 to 9.5)6.4 (0.2 to 15.7)0 (0.0 to 5.7)
Week 162.1 (-3.8 to 9.5)8.5 (1.9 to 18.4)0 (0.0 to 5.7)
Week 204.2 (-2.0 to 12.5)12.8 (5.2 to 23.6)0 (0.0 to 5.7)
Week 2412.5 (5.1 to 23.2)12.8 (5.2 to 23.6)0 (0.0 to 5.7)
SecondaryNumber of Participants With the IGA Score Change (Treatment Period)

The clinical evaluator of alopecia areata (AA) will perform an assessment of the overall improvement of AA and assign an Investigator Global Assessment (IGA) score(ranging from 0 to 5) with higher score representing higher regrowth rate. Baseline is defined as the last measurement prior to first dosing (Day 1).

Time frame:
baseline, Week 2,4,6,8,12,16,20,24
Reported as:
Count of participants · Participants
Number of Participants With the IGA Score Change (Treatment Period)
ParticipantsPF-06651600PF-06700841Placebo
Baseline — 0 (NO CHANGE OR FURTHER LOSS)484747
Baseline — 1 (1-24% REGROWTH)000
Baseline — 2 (25-49% REGROWTH)000
Baseline — 3 (50-74% REGROWTH)000
Baseline — 4 (75-99% REGROWTH)000
Baseline — 5 (100% REGROWTH)000
Week 2 — 0 (NO CHANGE OR FURTHER LOSS)404340
Week 2 — 1 (1-24% REGROWTH)845
Week 2 — 2 (25-49% REGROWTH)001
Week 2 — 3 (50-74% REGROWTH)000
Week 2 — 4 (75-99% REGROWTH)000
Week 2 — 5 (100% REGROWTH)000
Week 4 — 0 (NO CHANGE OR FURTHER LOSS)292136
Week 4 — 1 (1-24% REGROWTH)15196
Week 4 — 2 (25-49% REGROWTH)421
Week 4 — 3 (50-74% REGROWTH)050
Week 4 — 4 (75-99% REGROWTH)000
Week 4 — 5 (100% REGROWTH)000
Week 6 — 0 (NO CHANGE OR FURTHER LOSS)161035
Week 6 — 1 (1-24% REGROWTH)18176
Week 6 — 2 (25-49% REGROWTH)791
Week 6 — 3 (50-74% REGROWTH)241
Week 6 — 4 (75-99% REGROWTH)450
Week 6 — 5 (100% REGROWTH)000
Week 8 — 0 (NO CHANGE OR FURTHER LOSS)13733
Week 8 — 1 (1-24% REGROWTH)17179
Week 8 — 2 (25-49% REGROWTH)751
Week 8 — 3 (50-74% REGROWTH)330
Week 8 — 4 (75-99% REGROWTH)7111
Week 8 — 5 (100% REGROWTH)010
Week 12 — 0 (NO CHANGE OR FURTHER LOSS)13633
Week 12 — 1 (1-24% REGROWTH)111110
Week 12 — 2 (25-49% REGROWTH)991
Week 12 — 3 (50-74% REGROWTH)540
Week 12 — 4 (75-99% REGROWTH)8101
Week 12 — 5 (100% REGROWTH)140
Week 16 — 0 (NO CHANGE OR FURTHER LOSS)14531
Week 16 — 1 (1-24% REGROWTH)779
Week 16 — 2 (25-49% REGROWTH)791
Week 16 — 3 (50-74% REGROWTH)640
Week 16 — 4 (75-99% REGROWTH)10111
Week 16 — 5 (100% REGROWTH)150
Week 20 — 0 (NO CHANGE OR FURTHER LOSS)14429
Week 20 — 1 (1-24% REGROWTH)669
Week 20 — 2 (25-49% REGROWTH)871
Week 20 — 3 (50-74% REGROWTH)440
Week 20 — 4 (75-99% REGROWTH)10111
Week 20 — 5 (100% REGROWTH)380
Week 24 — 0 (NO CHANGE OR FURTHER LOSS)13427
Week 24 — 1 (1-24% REGROWTH)566
Week 24 — 2 (25-49% REGROWTH)751
Week 24 — 3 (50-74% REGROWTH)550
Week 24 — 4 (75-99% REGROWTH)8131
Week 24 — 5 (100% REGROWTH)670
SecondaryNumber of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Treatment Period

An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators.

Time frame:
baseline up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Treatment Period
ParticipantsPF-06651600PF-06700841Placebo
TEAE (All Causalities)323635
TEAE (Treatment Related)132014
SecondaryNumber of Participants With Laboratory Abnormalities During Treatment Period

Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect \& Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively.

Time frame:
Baseline up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities During Treatment Period
ParticipantsPF-06651600PF-06700841Placebo
With abnormalities without regard to baseline353632
Meeting Safety Criteria12295
Meeting Retest Criteria5189
Meeting Discontinuation Criteria030
SecondaryTime to Achieve the Retreatment Criteria During the Withdrawal/Retreatment Part of the Extension Period Among Subjects Who Achieved Primary Endpoint at Week 24 (SBE Period)

Time to re-treatment (weeks) = (date of re-treatment criteria met - date at Week 24 +1)/7. The calendar time to retreatment was calculated. Baseline is defined as Week 24 measurement. The duration in Drug Holiday #1 (ranging from 2-6 weeks) is counted in the Kaplan-Meier analysis. One subject directly entered the re-treatment period and hence is censored at baseline in the Kaplan-Meier analysis.

Time frame:
Week 24 up to Week 52
Reported as:
Number · Weeks
Time to Achieve the Retreatment Criteria During the Withdrawal/Retreatment Part of the Extension Period Among Subjects Who Achieved Primary Endpoint at Week 24 (SBE Period)
WeeksPF-06651600 RespondersPF-06700841 Responders
Q1 time to retreatment (25th percentile of time)10.1 (4.3 to 12.6)11.0 (4.1 to 16.1)
Median time to retreatment16.1 (10.1 to 20.3)24.1 (14.6 to NA)
Q3 time to retreatment (75th percentile of time)21.1 (16.1 to NA)NA (24.3 to NA)
SecondaryChange From Baseline in SALT Across Time (SBE Period)

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Least Square Mean and 90% confidence interval in this outcome measurement is the LSM and 90%CI for difference from initial 24-week treatment period placebo respectively.

Time frame:
Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)
Reported as:
Least squares mean · unit on a scale
Change From Baseline in SALT Across Time (SBE Period)
unit on a scaleActive Non-responders on PF-06651600Active Non-responders on PF-06700841Placebo Non-responders on PF-06651600Placebo Non-responders on PF-06700841Retreated PF-06651600 Responders in the Retreatment SegmentRetreated Responders on PF-06700841 in the Retreatment Segment
Week 30/ AT Week 21.76 (-4.47 to 7.99)0.09 (-9.83 to 10.01)2.99 (-4.56 to 10.54)-0.31 (-9.53 to 8.92)25.04 (15.01 to 35.08)19.83 (10.00 to 29.66)
Week 32/ AT Week 41.85 (-4.37 to 8.07)2.22 (-7.78 to 12.21)3.37 (-4.06 to 10.79)3.71 (-4.93 to 12.35)27.63 (17.67 to 37.59)15.66 (5.82 to 25.51)
Week 34/ AT Week 61.80 (-4.42 to 8.02)3.16 (-6.90 to 13.23)10.16 (2.55 to 17.77)24.67 (16.00 to 33.34)33.78 (23.72 to 43.83)20.09 (10.17 to 30.02)
Week 36/ AT Week 82.16 (-4.09 to 8.40)3.01 (-7.12 to 13.14)8.93 (1.34 to 16.52)42.32 (33.37 to 51.28)38.80 (28.75 to 48.84)27.35 (17.42 to 37.27)
Week 40/ AT Week 123.35 (-2.91 to 9.61)3.19 (-7.00 to 13.38)18.30 (10.73 to 25.86)50.27 (41.65 to 58.90)43.70 (33.58 to 53.82)39.28 (29.36 to 49.19)
Week 44/ AT Week 163.41 (-2.84 to 9.67)3.12 (-7.19 to 13.43)25.71 (17.70 to 33.72)54.69 (45.73 to 63.64)48.93 (38.59 to 59.27)50.58 (40.48 to 60.69)
Week 48/ AT Week 204.70 (-1.57 to 10.97)2.97 (-7.39 to 13.34)25.28 (17.42 to 33.13)62.45 (53.13 to 71.77)53.74 (43.39 to 64.09)53.79 (43.57 to 64.02)
Week 52/ AT Week 247.06 (0.75 to 13.38)3.01 (-7.47 to 13.49)28.88 (20.20 to 37.56)58.53 (49.42 to 67.63)55.94 (45.42 to 66.46)58.37 (48.11 to 68.64)
SecondaryPercentage of Participants Achieving SALT 30 Across Time (SBE Period)

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.

Time frame:
Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)
Reported as:
Number · percent of participants
Percentage of Participants Achieving SALT 30 Across Time (SBE Period)
percent of participantsActive Non-responders on PF-06651600Active Non-responders on PF-06700841Placebo Non-responders on PF-06651600Placebo Non-responders on PF-06700841Retreated PF-06651600 Responders in the Retreatment SegmentRetreated Responders on PF-06700841 in the Retreatment Segment
Week 30/ AT Week 24.1 (-5.3 to 23.0)-2.1 (-10.9 to 40.0)3.8 (-5.5 to 21.6)-2.1 (-9.7 to 18.9)47.9 (25.3 to 70.0)31.2 (12.8 to 54.0)
Week 32/ AT Week 44.1 (-5.3 to 23.0)-2.1 (-10.9 to 40.0)9.6 (-2.4 to 30.2)14.5 (0.4 to 39.4)62.2 (38.2 to 81.5)11.2 (-1.0 to 33.5)
Week 34/ AT Week 64.1 (-5.3 to 23.0)-2.1 (-10.9 to 40.0)21.4 (4.8 to 43.2)31.2 (10.9 to 57.0)69.3 (45.3 to 86.5)31.2 (12.8 to 54.0)
Week 36/ AT Week 84.1 (-5.3 to 23.0)-2.1 (-10.9 to 40.0)21.4 (4.8 to 43.2)56.2 (30.8 to 78.2)69.3 (45.3 to 86.5)44.5 (23.2 to 66.5)
Week 40/ AT Week 1210.4 (-1.5 to 31.8)-2.1 (-10.9 to 40.0)27.3 (8.5 to 49.6)81.2 (55.6 to 94.4)62.2 (38.2 to 81.5)51.2 (28.9 to 72.2)
Week 44/ AT Week 1610.4 (-1.5 to 31.8)-2.1 (-10.9 to 40.0)33.2 (15.2 to 54.5)64.5 (38.4 to 84.5)62.2 (38.2 to 81.5)51.2 (28.9 to 72.2)
Week 48/ AT Week 2010.4 (-1.5 to 31.8)-2.1 (-10.9 to 40.0)39.0 (20.0 to 60.1)64.5 (38.4 to 84.5)69.3 (45.3 to 86.5)51.2 (28.9 to 72.2)
Week 52/ AT Week 2410.4 (-1.5 to 31.8)-2.1 (-10.9 to 40.0)27.3 (8.5 to 49.6)64.5 (38.4 to 84.5)55.0 (31.6 to 76.0)51.2 (28.9 to 72.2)
SecondaryPercentage of Participants Achieving SALT 50 Across Time (SBE Period)

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 50 response is a 50% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.

Time frame:
Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving SALT 50 Across Time (SBE Period)
percentage of participantsActive Non-responders on PF-06651600Active Non-responders on PF-06700841Placebo Non-responders on PF-06651600Placebo Non-responders on PF-06700841Retreated PF-06651600 Responders in the Retreatment SegmentRetreated Responders on PF-06700841 in the Retreatment Segment
Week 30/ AT Week 20.0 (-6.3 to 17.1)0.0 (-7.4 to 45.1)0.0 (-6.2 to 16.2)0.0 (-6.3 to 22.1)14.3 (2.4 to 38.5)20.0 (5.7 to 44.0)
Week 32/ AT Week 40.0 (-6.3 to 17.1)0.0 (-7.4 to 45.1)0.0 (-6.2 to 16.2)0.0 (-6.3 to 22.1)21.4 (6.1 to 46.6)6.7 (-2.1 to 27.9)
Week 34/ AT Week 6-2.1 (-9.7 to 13.8)-2.1 (-10.9 to 40.0)9.6 (-2.4 to 30.2)31.2 (10.9 to 57.0)26.4 (6.1 to 50.0)11.2 (-1.0 to 33.5)
Week 36/ AT Week 8-2.1 (-9.7 to 13.8)-2.1 (-10.9 to 40.0)3.8 (-5.5 to 21.6)56.2 (30.8 to 78.2)33.6 (14.1 to 57.2)24.5 (5.6 to 47.1)
Week 40/ AT Week 12-2.1 (-9.7 to 13.8)-2.1 (-10.9 to 40.0)15.5 (1.1 to 36.8)56.2 (30.8 to 78.2)47.9 (25.3 to 70.0)44.5 (23.2 to 66.5)
Week 44/ AT Week 16-2.1 (-9.7 to 13.8)-2.1 (-10.9 to 40.0)21.4 (4.8 to 43.2)64.5 (38.4 to 84.5)47.9 (25.3 to 70.0)44.5 (23.2 to 66.5)
Week 48/ AT Week 204.1 (-5.3 to 23.0)-2.1 (-10.9 to 40.0)27.3 (8.5 to 49.6)64.5 (38.4 to 84.5)47.9 (25.3 to 70.0)37.9 (17.9 to 60.3)
Week 52/ AT Week 244.1 (-5.3 to 23.0)-2.1 (-10.9 to 40.0)27.3 (8.5 to 49.6)64.5 (38.4 to 84.5)47.9 (25.3 to 70.0)44.5 (23.2 to 66.5)
SecondaryPercentage of Participants Achieving SALT 75 Across Time (SBE Period)

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 75 response is a 75% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.

Time frame:
Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving SALT 75 Across Time (SBE Period)
percentage of participantsActive Non-responders on PF-06651600Active Non-responders on PF-06700841Placebo Non-responders on PF-06651600Placebo Non-responders on PF-06700841Retreated PF-06651600 Responders in the Retreatment SegmentRetreated Responders on PF-06700841 in the Retreatment Segment
Week 30/ AT Week 20.0 (-6.3 to 17.1)0.0 (-7.4 to 45.1)0.0 (-6.2 to 16.2)0.0 (-6.3 to 22.1)0.0 (-6.8 to 19.3)0.0 (-6.6 to 18.1)
Week 32/ AT Week 40.0 (-6.3 to 17.1)0.0 (-7.4 to 45.1)0.0 (-6.2 to 16.2)0.0 (-6.3 to 22.1)7.1 (-1.9 to 29.7)0.0 (-6.6 to 18.1)
Week 34/ AT Week 60.0 (-6.3 to 17.1)0.0 (-7.4 to 45.1)0.0 (-6.2 to 16.2)8.3 (-1.5 to 33.9)14.3 (2.4 to 38.5)6.7 (-2.1 to 27.9)
Week 36/ AT Week 8-2.1 (-9.7 to 13.8)-2.1 (-10.9 to 40.0)-2.1 (-9.7 to 13.3)22.9 (2.8 to 48.7)26.4 (6.1 to 50.0)17.9 (1.8 to 40.6)
Week 40/ AT Week 12-2.1 (-9.7 to 13.8)-2.1 (-10.9 to 40.0)3.8 (-5.5 to 21.6)39.5 (17.0 to 64.5)26.4 (6.1 to 50.0)31.2 (12.8 to 54.0)
Week 44/ AT Week 16-2.1 (-9.7 to 13.8)-2.1 (-10.9 to 40.0)15.5 (1.1 to 36.8)56.2 (30.8 to 78.2)26.4 (6.1 to 50.0)37.9 (17.9 to 60.3)
Week 48/ AT Week 20-2.1 (-9.7 to 13.8)-2.1 (-10.9 to 40.0)15.5 (1.1 to 36.8)64.5 (38.4 to 84.5)28.6 (6.1 to 50.0)37.9 (17.9 to 60.3)
Week 52/ AT Week 244.1 (-5.3 to 23.0)-2.1 (-10.9 to 40.0)27.3 (8.5 to 49.6)64.5 (38.4 to 84.5)33.6 (14.1 to 57.2)37.9 (17.9 to 60.3)
SecondaryPercentage of Participants Achieving SALT 90 Across Time (SBE Period)

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 90 response is a 90% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.

Time frame:
Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving SALT 90 Across Time (SBE Period)
percentage of participantsActive Non-responders on PF-06651600Active Non-responders on PF-06700841Placebo Non-responders on PF-06651600Placebo Non-responders on PF-06700841Retreated PF-06651600 Responders in the Retreatment SegmentRetreated Responders on PF-06700841 in the Retreatment Segment
Week 30/ AT Week 20.0 (-6.3 to 17.1)0.0 (-7.4 to 45.1)0.0 (-6.2 to 16.2)0.0 (-6.3 to 22.1)0.0 (-6.8 to 19.3)0.0 (-6.6 to 18.1)
Week 32/ AT Week 40.0 (-6.3 to 17.1)0.0 (-7.4 to 45.1)0.0 (-6.2 to 16.2)0.0 (-6.3 to 22.1)0.0 (-6.8 to 19.3)0.0 (-6.6 to 18.1)
Week 34/ AT Week 60.0 (-6.3 to 17.1)0.0 (-7.4 to 45.1)0.0 (-6.2 to 16.2)0.0 (-6.3 to 22.1)0.0 (-6.8 to 19.3)0.0 (-6.6 to 18.1)
Week 36/ AT Week 80.0 (-6.3 to 17.1)0.0 (-7.4 to 45.1)0.0 (-6.2 to 16.2)8.3 (-1.5 to 33.9)7.1 (-1.9 to 29.7)6.7 (-2.1 to 27.9)
Week 40/ AT Week 120.0 (-6.3 to 17.1)0.0 (-7.4 to 45.1)0.0 (-6.2 to 16.2)25.0 (7.2 to 52.7)14.3 (2.4 to 38.5)13.3 (2.1 to 36.3)
Week 44/ AT Week 160.0 (-6.3 to 17.1)0.0 (-7.4 to 45.1)0.0 (-6.2 to 16.2)33.3 (12.3 to 60.9)21.4 (6.1 to 46.6)20.0 (5.7 to 44.0)
Week 48/ AT Week 20-2.1 (-9.7 to 13.8)-2.1 (-10.9 to 40.0)3.8 (-5.5 to 21.6)47.9 (23.6 to 71.6)26.4 (6.1 to 50.0)24.5 (5.6 to 47.1)
Week 52/ AT Week 240.0 (-6.3 to 17.1)0.0 (-7.4 to 45.1)17.6 (5.0 to 39.6)50.0 (24.5 to 75.5)28.6 (10.4 to 54.0)40.0 (19.1 to 64.0)
SecondaryPercentage of Participants Achieving SALT 100 Across Time (SBE Period)

SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 100 response is a 100% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.

Time frame:
Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving SALT 100 Across Time (SBE Period)
percentage of participantsActive Non-responders on PF-06651600Active Non-responders on PF-06700841Placebo Non-responders on PF-06651600Placebo Non-responders on PF-06700841Retreated PF-06651600 Responders in the Retreatment SegmentRetreated Responders on PF-06700841 in the Retreatment Segment
Week 30/ AT Week 20.0 (-6.3 to 17.1)0.0 (-7.4 to 45.1)0.0 (-6.2 to 16.2)0.0 (-6.3 to 22.1)0.0 (-6.8 to 19.3)0.0 (-6.6 to 18.1)
Week 32/ AT Week 40.0 (-6.3 to 17.1)0.0 (-7.4 to 45.1)0.0 (-6.2 to 16.2)0.0 (-6.3 to 22.1)0.0 (-6.8 to 19.3)0.0 (-6.6 to 18.1)
Week 34/ AT Week 60.0 (-6.3 to 17.1)0.0 (-7.4 to 45.1)0.0 (-6.2 to 16.2)0.0 (-6.3 to 22.1)0.0 (-6.8 to 19.3)0.0 (-6.6 to 18.1)
Week 36/ AT Week 80.0 (-6.3 to 17.1)0.0 (-7.4 to 45.1)0.0 (-6.2 to 16.2)0.0 (-6.3 to 22.1)0.0 (-6.8 to 19.3)0.0 (-6.6 to 18.1)
Week 40/ AT Week 120.0 (-6.3 to 17.1)0.0 (-7.4 to 45.1)0.0 (-6.2 to 16.2)8.3 (-1.5 to 33.9)7.1 (-1.9 to 29.7)0.0 (-6.6 to 18.1)
Week 44/ AT Week 160.0 (-6.3 to 17.1)0.0 (-7.4 to 45.1)0.0 (-6.2 to 16.2)8.3 (-1.5 to 33.9)7.1 (-1.9 to 29.7)13.3 (2.1 to 36.3)
Week 48/ AT Week 200.0 (-6.3 to 17.1)0.0 (-7.4 to 45.1)0.0 (-6.2 to 16.2)8.3 (-1.5 to 33.9)7.1 (-1.9 to 29.7)20.0 (5.7 to 44.0)
Week 52/ AT Week 240.0 (-6.3 to 17.1)0.0 (-7.4 to 45.1)0.0 (-6.2 to 16.2)8.3 (-1.5 to 33.9)14.3 (2.4 to 38.5)20.0 (5.7 to 44.0)

Adverse events

Collected over From first dose of study treatment up to 113 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Period-Placebo0/47 (0%)0/47 (0%)26/47 (55.3%)
Treatment Period-PF-066516000/48 (0%)0/48 (0%)23/48 (47.9%)
Treatment Period-PF-067008410/47 (0%)2/47 (4.3%)28/47 (59.6%)
Single Blind Extension-Active Non-responders on PF-066516000/16 (0%)0/16 (0%)8/16 (50%)
Single Blind Extension-Placebo Non-responders on PF-066516000/17 (0%)0/17 (0%)12/17 (70.6%)
Single Blind Extension-Active Non-responders on PF-067008410/5 (0%)0/5 (0%)4/5 (80%)
Single Blind Extension-Placebo Non-responders on PF-067008410/12 (0%)0/12 (0%)10/12 (83.3%)
SBE-Non-Retreated PF-06651600 Responders in Withdrawal Segment0/8 (0%)0/8 (0%)4/8 (50%)
SBE-Retreated PF-06651600 Responders in Withdrawal Segment0/14 (0%)0/14 (0%)3/14 (21.4%)
SBE-Non-Retreated PF-06700841 Responders (Withdrawal Segment)0/9 (0%)0/9 (0%)6/9 (66.7%)
SBE-Retreated PF-06700841 Responders in the Withdrawal Segment0/14 (0%)0/14 (0%)9/14 (64.3%)
SBE-Retreated PF-06651600 Responders in Retreatment Segment0/14 (0%)0/14 (0%)11/14 (78.6%)
SBE-Retreated Responders on PF-06700841 in Retreatment Segment0/15 (0%)1/15 (6.7%)8/15 (53.3%)
Cross Over Extension-PF-066516000/5 (0%)0/5 (0%)4/5 (80%)
Cross Over Extension-PF-067008410/18 (0%)1/18 (5.6%)8/18 (44.4%)
Most frequent serious events
Most frequent serious events
EventTreatment Period-PlaceboTreatment Period-PF-06651600Treatment Period-PF-06700841Single Blind Extension-Active Non-responders on PF-06651600Single Blind Extension-Placebo Non-responders on PF-06651600Single Blind Extension-Active Non-responders on PF-06700841Single Blind Extension-Placebo Non-responders on PF-06700841SBE-Non-Retreated PF-06651600 Responders in Withdrawal SegmentSBE-Retreated PF-06651600 Responders in Withdrawal SegmentSBE-Non-Retreated PF-06700841 Responders (Withdrawal Segment)SBE-Retreated PF-06700841 Responders in the Withdrawal SegmentSBE-Retreated PF-06651600 Responders in Retreatment SegmentSBE-Retreated Responders on PF-06700841 in Retreatment SegmentCross Over Extension-PF-06651600Cross Over Extension-PF-06700841
Lower limb fractureInjury, poisoning and procedural complications0/470/480/470/160/170/50/120/80/140/90/140/141/150/50/18
Gastroenteritis salmonellaInfections and infestations0/470/481/470/160/170/50/120/80/140/90/140/140/150/51/18
RhabdomyolysisMusculoskeletal and connective tissue disorders0/470/482/470/160/170/50/120/80/140/90/140/140/150/50/18
Most frequent other events
Showing 10 of 104
Most frequent other events
EventTreatment Period-PlaceboTreatment Period-PF-06651600Treatment Period-PF-06700841Single Blind Extension-Active Non-responders on PF-06651600Single Blind Extension-Placebo Non-responders on PF-06651600Single Blind Extension-Active Non-responders on PF-06700841Single Blind Extension-Placebo Non-responders on PF-06700841SBE-Non-Retreated PF-06651600 Responders in Withdrawal SegmentSBE-Retreated PF-06651600 Responders in Withdrawal SegmentSBE-Non-Retreated PF-06700841 Responders (Withdrawal Segment)SBE-Retreated PF-06700841 Responders in the Withdrawal SegmentSBE-Retreated PF-06651600 Responders in Retreatment SegmentSBE-Retreated Responders on PF-06700841 in Retreatment SegmentCross Over Extension-PF-06651600Cross Over Extension-PF-06700841
Upper respiratory tract infectionInfections and infestations5/474/4811/472/160/171/51/121/80/141/92/142/141/151/53/18
FatigueGeneral disorders3/470/480/470/161/170/51/120/80/142/90/140/140/150/50/18
NasopharyngitisInfections and infestations6/476/484/470/162/170/52/120/81/141/90/143/141/151/50/18
HaematuriaRenal and urinary disorders0/470/480/470/160/171/50/120/80/140/90/140/140/150/50/18
PruritusSkin and subcutaneous tissue disorders0/470/480/470/160/171/51/120/80/140/91/140/140/151/50/18
IgA nephropathyRenal and urinary disorders0/470/480/470/160/171/50/120/80/140/90/140/140/150/50/18
NephrolithiasisRenal and urinary disorders0/470/480/470/160/171/50/120/80/140/90/140/140/150/50/18
ProteinuriaRenal and urinary disorders0/470/480/470/160/171/50/120/80/140/90/140/140/150/50/18
Blood creatinine increasedInvestigations0/470/480/470/160/171/51/120/80/140/90/140/141/150/50/18
Herpes simplexInfections and infestations0/470/480/470/160/171/50/120/80/140/90/140/140/150/50/18

Baseline characteristics

All participants received at least 1 dose of PF-06651600,PF-06700841 or matching placebo.

Age, Continuous
Age, Continuous(years)TP:PlaceboTP:PF-06651600TP:PF-06700841Total
Mean38.17 ± 14.2236.88 ± 12.6233.94 ± 11.4336.33 ± 12.84
Age, Customized
Age, Customized(Participants)TP:PlaceboTP:PF-06651600TP:PF-06700841Total
18-44 Years313340104
45-64 Years1514635
>=65 Years1113
Sex: Female, Male
Sex: Female, Male(Participants)TP:PlaceboTP:PF-06651600TP:PF-06700841Total
Female29373298
Male18111544
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TP:PlaceboTP:PF-06651600TP:PF-06700841Total
Hispanic or Latino23510
Not Hispanic or Latino454542132
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TP:PlaceboTP:PF-06651600TP:PF-06700841Total
White453836119
Black or African American0437
Asian2338
American Indian or Alaska Native0011
Native Hawaiian or Other Pacific Islander0000
other0347
08

Study locations

55 sites
  • University of Alabama at Birmingham, Dermatology at the Whitaker Clinic
    Birmingham, Alabama 35233, United States
  • University of Alabama at Birmingham, The Kirklin Clinic
    Birmingham, Alabama 35233, United States
  • Southern California Dermatology, Inc.
    Santa Ana, California 92701, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • Office of F. Monte Purcelli
    Santa Monica, California 90404, United States
  • Tower Saint John's Imaging
    Santa Monica, California 90404, United States
  • University of Colorado Hospital Clinical and Translational Research Center, Inpatient Unit
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital Clinical and Translational Research Center, Outpatient Clinic
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital, Anschutz Cancer Pavilion
    Aurora, Colorado 80045, United States
  • Yale School of Medicine
    New Haven, Connecticut 06510, United States
  • Investigational Drug Services
    New Haven, Connecticut 06511, United States
  • Church Street Research Unit
    New Haven, Connecticut 06519, United States
  • Yale Hearing and Balance Center
    New Haven, Connecticut 06519, United States
  • Yale New Haven Hospital
    New Haven, Connecticut 06519, United States
  • Park Avenue Dermatology Administrative Annex
    Orange Park, Florida 32073, United States
  • Park Avenue Dermatology
    Orange Park, Florida 32073, United States
  • Edward B. Kampsen, MD
    Tampa, Florida 33609, United States
  • Olympian Clinical Research
    Tampa, Florida 33609, United States
  • Rose Radiology
    Tampa, Florida 33609, United States
  • Forward Clinical Trials, Inc
    Tampa, Florida 33624, United States
  • MedaPhase Inc.
    Newnan, Georgia 30263, United States
  • NorthShore University HealthSystem Dermatology Clinical Trials Unit
    Skokie, Illinois 60077, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46256, United States
  • Dawes Fretzin Dermatology Group, LLC
    Indianapolis, Indiana 46256, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Massachusetts General Hospital Clinical Unit for Research Trials in Skin (CURTIS)
    Boston, Massachusetts 02114, United States
  • Weill Cornell Medicine
    New York, New York 10021, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Mount Sinai Department of Otolaryngology
    New York, New York 10029, United States
  • Rockefeller University Hospital
    New York, New York 10065, United States
  • Investigational Drug Service
    Rochester, New York 14642, United States
  • University of Rochester Audiology
    Rochester, New York 14642, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • University of Rochester Radiology
    Rochester, New York 14642, United States
  • Vital Prospects Clinical Research Institute, P.C.
    Tulsa, Oklahoma 74136, United States
  • Health Concepts
    Rapid City, South Dakota 57702, United States
  • University of Utah MidValley Dermatology
    Murray, Utah 84107, United States
  • University of Utah Medical Center
    Salt Lake City, Utah 84132, United States
  • Virginia Clinical Research, Inc.
    Norfolk, Virginia 23502, United States
  • Hearing Life
    Hurstville, New South Wales 2220, Australia
  • Dr. Glen and Partners Medical Imaging
    Kogarah, New South Wales 2217, Australia
  • St George Dermatology and Skin Cancer Centre
    Kogarah, New South Wales 2217, Australia
  • St. George Hearing and Balance Clinic
    Kogarah, New South Wales 2217, Australia
  • The Skin Centre
    Benowa, Queensland 4217, Australia
  • Veracity Clinical Research
    Woolloongabba, Queensland 4102, Australia
  • Skin & Cancer Foundation Inc.
    Carlton, Victoria 3053, Australia
  • Sinclair Dermatology
    East Melbourne, Victoria 3002, Australia
  • Bridge Road Imag ing
    Richmond, Victoria 3121, Australia
  • Richmond Audiology
    Richmond, Victoria 3121, Australia
  • Wiseman Dermatology Research Inc.
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Lynderm Research Inc.
    Markham, Ontario L3P 1X2, Canada
  • Research by ICLS
    Oakville, Ontario L6J 7W5, Canada
  • SKiN Centre for Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • The Centre for Dermatology
    Richmond Hill, Ontario L4B 1A5, Canada
  • York Dermatology Center
    Richmond Hill, Ontario L4C 9M7, Canada
09

References and documents

Publications

  • Hughes JH, Qiu R, Banfield C, Dowty ME, Nicholas T. Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients. Clin Pharmacol Drug Dev. 2022 Dec;11(12):1447-1456. doi: 10.1002/cpdd.1163. Epub 2022 Aug 31. PubMed 36045513 ↗
  • Peeva E, Guttman-Yassky E, Banerjee A, Sinclair R, Cox LA, Zhu L, Zhu H, Vincent M, King B. Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial. J Am Acad Dermatol. 2022 Aug;87(2):390-393. doi: 10.1016/j.jaad.2021.12.008. Epub 2021 Dec 13. No abstract available. PubMed 34915057 ↗
  • Guttman-Yassky E, Pavel AB, Diaz A, Zhang N, Del Duca E, Estrada Y, King B, Banerjee A, Banfield C, Cox LA, Dowty ME, Page K, Vincent MS, Zhang W, Zhu L, Peeva E. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. J Allergy Clin Immunol. 2022 Apr;149(4):1318-1328. doi: 10.1016/j.jaci.2021.10.036. Epub 2021 Dec 1. PubMed 34863853 ↗
  • Fensome A, Ambler CM, Arnold E, Banker ME, Brown MF, Chrencik J, Clark JD, Dowty ME, Efremov IV, Flick A, Gerstenberger BS, Gopalsamy A, Hayward MM, Hegen M, Hollingshead BD, Jussif J, Knafels JD, Limburg DC, Lin D, Lin TH, Pierce BS, Saiah E, Sharma R, Symanowicz PT, Telliez JB, Trujillo JI, Vajdos FF, Vincent F, Wan ZK, Xing L, Yang X, Yang X, Zhang L. Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). J Med Chem. 2018 Oct 11;61(19):8597-8612. doi: 10.1021/acs.jmedchem.8b00917. Epub 2018 Aug 16. PubMed 30113844 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in May 2019, 29 months.

Results were first posted in May 2020, 1 year after primary completion.

Of 30 phase 2 interventional studies under Alopecia Areata, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 29 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2016
First posted
Nov 29, 2016
StartActual
Dec 15, 2016
Primary completionActual
May 15, 2019
CompletionActual
May 15, 2019
Results first posted
May 26, 2020
Last update
May 26, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02974868
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 29, 2016
Start date
Dec 15, 2016
Primary completion
May 15, 2019
Completion
May 15, 2019
Results posted
May 26, 2020
Last update
May 26, 2020

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PF-06651600 · PF-06700841

Start the discussion